Lewis K, Maio M, Demidov L, et al. BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma. ESMO 2017, abstract LBA7_PR.
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker